Ikena Oncology

Ikena Oncology, Inc.

0 Investors

Targeted Oncology Therapies

BOSTON, MA

Ikena Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. It concentrates on developing novel, biomarker-driven treatments for specific patient populations by addressing key signaling pathways that contribute to cancer growth, spread, and therapeutic resistance. The company is currently prioritizing its lead candidate while navigating a dynamic corporate landscape that includes a recent merger.

Products & Team

IK-595

Targeted Cancer TherapySeed

IK-595 is an orally administered MEK-RAF molecular glue, which is Ikena's lead clinical candidate. It is designed to trap MEK and RAF proteins in an inactive complex, leading to a more complete inhibition of the RAS signaling pathway. The therapy is currently in a Phase I clinical trial for patients with cancers characterized by RAS and RAF mutations.

Value Proposition

IK-595 aims to solve the problem of therapeutic resistance in cancer patients with RAS or RAF mutations, offering a potential new treatment option for those who have not responded to existing therapies or have developed resistance to them.

Pain Points

The therapies address the critical unmet need of cancer patients whose tumors have become resistant to existing treatments or who have cancers that are historically difficult to treat due to their underlying genetic drivers.

Acts as a 'molecular glue' to trap MEK and RAF in an inactive state, a distinct mechanism from traditional inhibitors.Designed to prevent signaling bypass that leads to therapeutic resistance by complexing with RAFs, including CRAF.Addresses the kinase-independent, anti-apoptotic function of CRAF, a mechanism not targeted by first-generation MEK or pan-RAF inhibitors.